ALVOW
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$0.30
−6.25%Price chart
Jul 14Jul 21Jul 24Aug 10Aug 17Aug 21Aug 26Sep 4
ValuationView details →
P/E (Fwd)
2.0x
EV/EBITDA
−981.8x
Market Cap
$90.07M
MomentumView details →
1D Return
−6.25%
YTD Return
−53.09%
RSI (14)
52.7
ValuationView details →
P/E (Fwd)
2.0x
EV/EBITDA
−981.8x
Market Cap
$90.07M
RSI (14)
52.7
MomentumView details →
1D Return
−6.25%
YTD Return
−53.09%
Similar companies
Latest newsMore news →
Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for its proposed biosimilars AVT34 (durvalumab) and AVT87 (emicizumab) in the U.S. and selected Asian markets.14d agoAlvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.16d agoAlvotech announced that the FDA closed its inspection of its manufacturing facility in Reykjavik, Iceland, with a Voluntary Action Indicated classification.37d ago